Hemab
Clinical-stage biotechnology company developing prophylactic therapies for bleeding and coagulation disorders. Activities span discovery and preclinical development through early/mid-stage clinical trials, CMC and drug product development, bioanalysis/DMPK, regulatory affairs, and pharmacovigilance. Uses antibody- and peptide-based modalities and conducts natural history and real-world studies and patient-centered research to inform trial and product design and pipeline prioritization.
Industries
Nr. of Employees
small (1-50)
Products
Platelet-targeted bispecific antibody therapeutic (clinical-stage)
Bispecific antibody constructs engineered to localize to activated platelets and provide coagulation factor–mimetic activity as a prophylactic therapy for platelet function disorders; progressed into early- to mid-stage clinical studies (Phase 1/2 and Phase 2 long-term extension).
Monovalent antibody therapeutic to increase endogenous coagulation proteins (clinical-stage)
Monovalent antibody approach developed to accumulate or stabilize endogenous von Willebrand Factor or other coagulation proteins as a prophylactic treatment option to prevent or reduce frequency of bleeding events.
Subcutaneous peptide-based antifibrinolytic therapeutic (preclinical/clinical development)
Subcutaneously administered peptide designed to inhibit plasmin-mediated fibrinolysis independent of the plasminogen activation pathway, developed as a potential non-hormonal prophylactic option for heavy menstrual bleeding and other indications.
HMB-003
A subcutaneously administered peptide-based plasmin inhibitor designed to directly block fibrinolysis independent of the plasminogen activation pathway, offering a potential non-hormonal alternative for the prophylactic management of heavy menstrual bleeding.
HMB-002
A prophylactic treatment being developed to support restoration of hemostasis in people with Von Willebrand Disease using a convenient subcutaneous treatment administration.
Sutacimig
An investigational biologic therapy being evaluated in clinical trials for the treatment of congenital Factor VII deficiency and Glanzmann thrombasthenia.
Platelet-targeted bispecific antibody therapeutic (clinical-stage)
Bispecific antibody constructs engineered to localize to activated platelets and provide coagulation factor–mimetic activity as a prophylactic therapy for platelet function disorders; progressed into early- to mid-stage clinical studies (Phase 1/2 and Phase 2 long-term extension).
Monovalent antibody therapeutic to increase endogenous coagulation proteins (clinical-stage)
Monovalent antibody approach developed to accumulate or stabilize endogenous von Willebrand Factor or other coagulation proteins as a prophylactic treatment option to prevent or reduce frequency of bleeding events.
Subcutaneous peptide-based antifibrinolytic therapeutic (preclinical/clinical development)
Subcutaneously administered peptide designed to inhibit plasmin-mediated fibrinolysis independent of the plasminogen activation pathway, developed as a potential non-hormonal prophylactic option for heavy menstrual bleeding and other indications.
HMB-003
A subcutaneously administered peptide-based plasmin inhibitor designed to directly block fibrinolysis independent of the plasminogen activation pathway, offering a potential non-hormonal alternative for the prophylactic management of heavy menstrual bleeding.
HMB-002
A prophylactic treatment being developed to support restoration of hemostasis in people with Von Willebrand Disease using a convenient subcutaneous treatment administration.
Sutacimig
An investigational biologic therapy being evaluated in clinical trials for the treatment of congenital Factor VII deficiency and Glanzmann thrombasthenia.
Expertise Areas
- Antibody and multispecific therapeutic discovery
- Peptide antifibrinolytic therapeutic development
- Clinical trial design and operations (Phase 1–2 and extensions)
- Natural history and real-world evidence studies
Key Technologies
- Bispecific antibody engineering
- Monovalent antibody strategies for endogenous protein accumulation
- Peptide-based antifibrinolytic agents
- Platelet-targeted delivery strategies
News & Updates
Announcement of the first participant dosed in a Phase 1 study of a subcutaneously administered peptide-based plasmin inhibitor targeting heavy menstrual bleeding.
Report of full enrollment in a Phase 2 clinical trial evaluating a prophylactic antibody designed to prevent bleeding events in a platelet function disorder.
Interim clinical data from a Phase 2 program and multiple presentations of clinical and preclinical data at ISTH congresses.
Presentation material and reporting related to first-in-human investigation of a monovalent antibody prophylactic in von Willebrand Disease at a scientific congress.
Multiple conference presentations describing bleeding burden, psychological impact, and long-term extension results for prophylactic programs in Glanzmann thrombasthenia and related analyses presented at ISTH 2026.
VELORA Pioneer is a Phase 1/2 interventional trial evaluating a prophylactic monovalent antibody in VWD; VELORA Discover is a prospective natural history screening study to contextualize trial outcomes.
Announcement of the first participant dosed in a Phase 1 study of a subcutaneously administered peptide-based plasmin inhibitor targeting heavy menstrual bleeding.
Report of full enrollment in a Phase 2 clinical trial evaluating a prophylactic antibody designed to prevent bleeding events in a platelet function disorder.
Interim clinical data from a Phase 2 program and multiple presentations of clinical and preclinical data at ISTH congresses.
Presentation material and reporting related to first-in-human investigation of a monovalent antibody prophylactic in von Willebrand Disease at a scientific congress.
Multiple conference presentations describing bleeding burden, psychological impact, and long-term extension results for prophylactic programs in Glanzmann thrombasthenia and related analyses presented at ISTH 2026.
VELORA Pioneer is a Phase 1/2 interventional trial evaluating a prophylactic monovalent antibody in VWD; VELORA Discover is a prospective natural history screening study to contextualize trial outcomes.